Literature DB >> 33507942

Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model.

Corrine Nief1, Robert Morhard1, Erika Chelales1, Daniel Adrianzen Alvarez1, Ioanna Bourla Bs1, Christopher T Lam1, Alan A Sag2, Brian T Crouch1,3, Jenna L Mueller1, David Katz1,4, Mark W Dewhirst5, Jeffrey I Everitt6, Nirmala Ramanujam1,7,8.   

Abstract

Focal tumor ablation with ethanol could provide benefits in low-resource settings because of its low overall cost, minimal imaging technology requirements, and acceptable clinical outcomes. Unfortunately, ethanol ablation is not commonly utilized because of a lack of predictability of the ablation zone, caused by inefficient retention of ethanol at the injection site. To create a predictable zone of ablation, we have developed a polymer-assisted ablation method using ethyl cellulose (EC) mixed with ethanol. EC is ethanol-soluble and water-insoluble, allowing for EC-ethanol to be injected as a liquid and precipitate into a solid, occluding the leakage of ethanol upon contact with tissue. The aims of this study were to compare the 1) safety, 2) release kinetics, 3) spatial distribution, 4) necrotic volume, and 5) overall survival of EC-ethanol to conventional ethanol ablation in a murine breast tumor model. Non-target tissue damage was monitored through localized adverse events recording, ethanol release kinetics with Raman spectroscopy, injectate distribution with in vivo imaging, target-tissue necrosis with NADH-diaphorase staining, and overall survival by proxy of tumor growth. EC-ethanol exhibited decreased localized adverse events, a slowing of the release rate of ethanol, more compact injection zones, 5-fold increase in target-tissue necrosis, and longer overall survival rates compared to the same volume of pure ethanol. A single 150 μL dose of 6% EC-ethanol achieved a similar survival probability rates to six daily 50 μL doses of pure ethanol used to simulate a slow-release of ethanol over 6 days. Taken together, these results demonstrate that EC-ethanol is safer and more effective than ethanol alone for ablating tumors.

Entities:  

Year:  2021        PMID: 33507942     DOI: 10.1371/journal.pone.0234535

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  4 in total

1.  Optimizing ethyl cellulose-ethanol delivery towards enabling ablation of cervical dysplasia.

Authors:  Jenna L Mueller; Robert Morhard; Michael DeSoto; Erika Chelales; Jeffrey Yang; Corrine Nief; Brian Crouch; Jeffrey Everitt; Rebecca Previs; David Katz; Nimmi Ramanujam
Journal:  Sci Rep       Date:  2021-08-19       Impact factor: 4.996

2.  Radiologic-pathologic analysis of increased ethanol localization and ablative extent achieved by ethyl cellulose.

Authors:  Erika Chelales; Robert Morhard; Corrine Nief; Brian Crouch; Jeffrey I Everitt; Alan Alper Sag; Nirmala Ramanujam
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

3.  Targeting Tumor Acidosis and Regulatory T Cells Unmasks Anti-Metastatic Potential of Local Tumor Ablation in Triple-Negative Breast Cancer.

Authors:  Corrine A Nief; Alana Gonzales; Erika Chelales; Júlia Sroda Agudogo; Brian T Crouch; Smita K Nair; Nirmala Ramanujam
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

4.  Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models.

Authors:  Corrine A Nief; Adam M Swartz; Erika Chelales; Lauren Y Sheu; Brian T Crouch; Nirmala Ramanujam; Smita K Nair
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.